Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Quarterly Earnings Results

Lexicon Pharmaceuticals (NASDAQ:LXRX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The firm had revenue of $294.45 million for the quarter, compared to analysts’ expectations of $12.00 million. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.26) EPS.

Shares of NASDAQ:LXRX traded down $0.36 during trading on Friday, hitting $3.52. The company had a trading volume of 1,316,800 shares, compared to its average volume of 1,292,482. Lexicon Pharmaceuticals has a one year low of $1.13 and a one year high of $9.15. The company has a fifty day simple moving average of $3.52 and a two-hundred day simple moving average of $4.21. The stock has a market cap of $419.77 million, a price-to-earnings ratio of -3.09 and a beta of 0.95.

Several research firms have weighed in on LXRX. Gabelli upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, September 11th. ValuEngine upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Citigroup cut Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price target for the company from $3.00 to $4.00 in a report on Friday. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a report on Saturday. Finally, BidaskClub cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $6.45.

In other Lexicon Pharmaceuticals news, Director Christopher J. Sobecki bought 99,249 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $2.41 per share, for a total transaction of $239,190.09. Following the purchase, the director now directly owns 13,645 shares in the company, valued at $32,884.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Lonnel Coats bought 37,000 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $1.35 per share, for a total transaction of $49,950.00. Following the completion of the purchase, the chief executive officer now owns 87,695 shares in the company, valued at $118,388.25. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 255,749 shares of company stock worth $578,510. 6.40% of the stock is owned by company insiders.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Recommended Story: Options Trading – What is a Straddle?

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.